ArticleRisk management and healthcare policy2024
Recombinant Human Follicle-Stimulating Hormone in Controlled Ovarian Hyperstimulation with Assisted Reproductive Technology in China: A Cost-Effectiveness Analysis.
Hongchao Li et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.